Should We Develop an Inhaled Anti-pneumococcal Vaccine for Adults?

ISSN: 2211-3533 (Online)
ISSN: 2211-3525 (Print)

Volume 14, 2 Issues, 2016

Download PDF Flyer

Anti-Infective Agents

Formerly: Anti-Infective Agents in Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Should We Develop an Inhaled Anti-pneumococcal Vaccine for Adults?

Anti-Infective Agents, 4(1): 75-89.

Author(s): Stephen B. Gordon and Neil French.

Affiliation: Malawi-Liverpool-Wellcome Programme of Clinical Tropical Research, Universities of Malawi and Liverpool (UK), PO Box 30096, Blantyre, Malawi.


Streptococcus pneumoniae is the most important bacterial cause of pneumonia and meningitis among adults. It is also a common cause of bacteraemia among HIV infected adults with rates of disease approaching 100 times normal community incidence figures. Rates of antibiotic resistance are rising among pneumococcal isolates globally and the currently available 23-valent pneumococcal polysaccharide vaccine is ineffective in HIV infected adult populations. The newer conjugate vaccine has been highly effective in children in the developed world. It may also offer some promise in adult risk populations, but it is expensive and has limited serotype coverage. This article reviews the epidemiology of pneumococcal disease, the current state of pneumococcal vaccines, the pathogenesis of pneumococcal disease, the potential advantages of an inhaled vaccine in adults and some of the chemical obstacles to producing such a vaccine.


streptococcus pneumoniae, pneumococcal disease, vaccination, inhalation, innate immunity.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 4
Issue Number: 1
First Page: 75
Last Page: 89
Page Count: 15
DOI: 10.2174/1568012052931269
Superbugs USA

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science